In this proposal the Principal Investigator is proposing to investigate the mechanism(s) that may be responsible for a sustained reduction in plasma HIV-1 RNA levels despite the appearance of dual drug-resistant mutations in some HIV-1-infected individuals treated with a combined zidovudine (ZDV) plus either lamivudine (3TC) or nevirapine (NVP). The PI is hypothesizing that durable suppression of viremia may result from a combination of factors, including: (1) emergence of drug-resistant viruses that contain """"""""suppressor"""""""" genetic mutations with HIV-1 reverse transcriptase (RT) during multi-drug therapy in vivo that restore drug susceptibility in vitro (e.g., RT mutations associated with either 3TC or NVP therapy suppress ZDV resistance); and (2) selection of drug-resistant viruses that have attenuated replicative capacity (i.e., viruses that are """"""""less fit"""""""" than wild type). The PI is proposing to: (1) identify multiple mutations in the reverse transcriptase (RT) of clinical HIV-1 isolates that together confer dual- or triple-drug resistance; undertake detailed phenotypic and genotypic characterization of selected clinical HIV-1 isolates; confirm that dual- or triple-resistance-conferring mutations occur at the clonal level; and identify novel resistance mutations that develop during combination therapy; (2) investigate potential mechanism(s) for sustained reductions in viral burden in certain HIV-1 infected subjects over the time despite the emergence of dual-and triple-drug resistance during combination therapy. The focus will be on the evolution and the patterns of genetic drug resistance over time in selected subjects, particularly looking for the presence of """"""""suppressor"""""""" genetic RT mutations in HIV-1 isolates that result in restored phenotypic drug susceptibility in vitro. The results of serial phenotypic and genotypic drug resistance analyses will be linked to results of other virologic assays (i.e., determination of plasma viral burden and presence of syncytium-inducing (SI) viral phenotype) to identify those virologic factors most critical for sustained response; and (3) investigate the biologic properties of clinical HIV-1 isolates derived from 3TC-treated subjects with respect to enzymatic activity, viral replicative capacity, and genetic stability. It is expected that the understanding of the mechanism(s) that contribute to sustained HIV-1 suppression may allow definition of more rationale therapeutic strategies for treatment of HIV-1 individuals.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI040876-01
Application #
2005431
Study Section
Special Emphasis Panel (ZRG5-AAR (03))
Project Start
1996-12-01
Project End
2000-11-30
Budget Start
1996-12-01
Budget End
1997-11-30
Support Year
1
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Kuritzkes, Daniel R; Bassett, Roland L; Hazelwood, J Darren et al. (2004) Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens. J Acquir Immune Defic Syndr 36:600-3
Eron Jr, Joseph J; Bartlett, John A; Santana, Jorge L et al. (2004) Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. J Acquir Immune Defic Syndr 37:1581-3
Meyer, Peter R; Matsuura, Suzanne E; Zonarich, Dianna et al. (2003) Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase. J Virol 77:6127-37
Demeter, Lisa M; Bosch, Ronald J; Coombs, Robert W et al. (2002) Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter. J Clin Microbiol 40:2089-94
Johnson, V A; Petropoulos, C J; Woods, C R et al. (2001) Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. J Infect Dis 183:1688-93
Coghlan, M E; Sommadossi, J P; Jhala, N C et al. (2001) Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis 33:1914-21
Call, S A; Saag, M S; Westfall, A O et al. (2001) Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection. J Infect Dis 183:401-8
Fiscus, S A; Adimora, A A; Schoenbach, V J et al. (1999) Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina. J Infect Dis 180:99-105